The U.S. Food and Drug Administration (FDA) has announced a significant recall of duloxetinea commonly prescribed antidepressant. The recall affects nearly 360,000 bottles of the generic version of Cymbaltadistributed nationwide. The cause for concern is elevated levels of nitrosaminesa chemical compound that may increase the risk of cancer with prolonged exposure.
This recall is not an isolated incident but part of a growing trend of drug recalls due to nitrosamine contamination. The FDA has classified this as a Class II recallindicating that while the risk of serious health consequences is remote, temporary or medically reversible adverse effects are possible.
The specifics of the duloxetine recall
The recall involves duloxetine delayed-release capsules in both 30-mg and 60-mg strengths. The affected batches were manufactured by Towa Pharmaceutical and distributed by Breckenridge Pharmaceutical. The recall was initiated on June 4, 2026and includes multiple lot codes and expiration dates.
For the 30-mg capsules, the recalled lot code is 241180Cwith an expiration date of April 2027. The 60-mg capsules have several affected lot codes, with expiration dates ranging from November 2026 to May 2027. Patients are advised to check their medication against the provided lot codes and expiration dates.
Understanding the risks of nitrosamines
Nitrosamines are a class of chemicals that have been linked to an increased risk of cancer with long-term exposure above acceptable limits. The specific nitrosamine found in the recalled duloxetine is N-nitroso-duloxetine. While the FDA states that nitrosamines are commonly found in various foods and water, the concern arises when they are present in medications at levels exceeding safety thresholds.
The FDA has set acceptable daily intake limits for nitrosamines in medications. According to the agency, a person taking a medication containing nitrosamines at or below these limits every day for 70 years would not be expected to face an increased cancer risk. However, the recalled duloxetine batches contain levels of nitrosamines that exceed these limits.
What patients should do
Patients who have been prescribed duloxetine are advised not to stop taking their medication abruptly. Suddenly discontinuing duloxetine can lead to withdrawal symptoms that may begin within hours and persist for up to six weeks. Instead, patients should contact their healthcare provider or pharmacist for guidance on next steps.
Healthcare providers can offer alternative treatment options or replacement medication for affected patients. It is crucial for patients to discuss their concerns with a medical professional to ensure they continue to receive appropriate treatment for their condition.
The recall serves as a reminder of the importance of regular communication between patients and healthcare providers, especially when changes in medication occur. By staying informed and proactive, patients can help manage potential risks associated with their medications.
